Pfizer Reaches Three Settlements in Vyndamax Patent Infringement Suits
28 april, 16:32
10:32 AM EDT, 04/28/2026 (MT Newswires) -- Pfizer (PFE) said Tuesday it entered into settlement agreements with three generic drug manufacturers regarding lawsuits filed in the US District Court for the District of Delaware for patent infringement related to Vyndamax, a cardiomyopathy transthyretin-mediated amyloidosis treatment.
The settlements extend the drug's effective US patent expiry date to June 1, 2031, subject to the outcome of other litigation, the company said.
"Pfizer had previously anticipated a significant decline in U.S. revenues for Vyndamax beginning in 2029 upon patent expiry,"Pfizer said. "As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031."
Price: 26.65, Change: -0.15, Percent Change: -0.54
Ämnen i artikeln
Pfizer Reaches Three Settlements in Vyndamax Patent Infringement Suits
28 april, 16:32
10:32 AM EDT, 04/28/2026 (MT Newswires) -- Pfizer (PFE) said Tuesday it entered into settlement agreements with three generic drug manufacturers regarding lawsuits filed in the US District Court for the District of Delaware for patent infringement related to Vyndamax, a cardiomyopathy transthyretin-mediated amyloidosis treatment.
The settlements extend the drug's effective US patent expiry date to June 1, 2031, subject to the outcome of other litigation, the company said.
"Pfizer had previously anticipated a significant decline in U.S. revenues for Vyndamax beginning in 2029 upon patent expiry,"Pfizer said. "As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031."
Price: 26.65, Change: -0.15, Percent Change: -0.54
Ämnen i artikeln
Analys
Rapporter
Analys
Rapporter
Marknadsöversikt
1 DAG %
Senast
1 mån
